Introduction
Interferons are antiviral cytokines. They influence cell growth and modulate the immune system [1] . There are two classes of interferons:
Class I interferons
Interferon-␣ and interferon-␤ can be produced by almost any cell type in response to viral and other infections. They are encoded by at least 18 genes clustered on chromosome 9, made up of 165 or 166 amino acids, and have a molecular weight of approximately 20 kD.
Class II interferon
Interferon-␥, produced by T-cells and natural killer cells, is encoded by a single gene located on chromosome 12, made up of approximately 127 to 143 amino acids, and has a molecular weight of approximately 90 kD. Interferon-␥ has effects similar to those of class I interferon, but it differs in having a strong stimulating effect on the immune system.
Interferons are used in treating a wide range of diseases. Interferon-␣ is effective in chronic idiopathic myeloid leukemia, myelofibrosis, cutaneous T-cell lymphoma, multiple myeloma, melanoma, follicular B-cell lymphoma, and hairy cell leukemia. It is a preferred drug for treating hepatitis-C [1]. Interferon-␣ has been shown to benefit patients with pulmonary metastases. Interferon-␤ is mainly used to treat multiple sclerosis. Interferon-␥ is used for chronic granulomatous disease and has also been tried to control idiopathic pulmonary fibrosis.
The common side effects of interferons are fever, chills, chest tightness, bone and muscle aches, headaches, and depression. Interferons may also exacerbate autoimmune disorders including lupus erythematosus, hemolytic anemia, thyroiditis, rheumatoid arthritis, idiopathic thrombocytopenic purpura, monoclonal gammopathy, and nonspecific polyarthropathy [2,3]. Some of these patients had evidence of a preexisting subclinical illness that was triggered by interferon whereas, in other patients the drug appeared to have caused de novo appearance of the illness [2,4,5]. Nevertheless, pulmonary toxicity with clinical evidence of pneumonitis occurs in less than 1% of the patients [2,3]. The association of interferon-␥ and sarcoidosis has also been described infrequently. We describe three unusual cases of interferon-induced sarcoidosis and review the relevant literature.
Case reports
The following cases represent our experience with interferon induced sarcoidosis.
Case #1
In 1992, this 49-year-old Caucasian woman developed hepatitis. She was given interferon-␣ and ribavirin. After three months, the patient developed dry cough and dyspnea on moderate exertion. Physical examination was positive only for bilateral, fine crackles occupying the lower parts of both lungs. A chest roentgenogram showed questionable reticulo-nodular changes, but chest CT scan was consistent with moderate interstitial lung disease ( Fig. 1 ). Gallium scan was markedly positive (Fig. 2 ). Lung biopsy showed noncaseating granulomas (Fig. 3 ). The patient also had an elevated serum angiotensin-converting enzyme level, hypercalcemia, and hypercalciuria. The diagnosis of multisystem sarcoidosis was clear. It was decided not to give her prednisone, but to discontinue her interferon-ribavirin combination. After a few months, her sarcoidosis subsided; chest CT scan, serum angiotensin converting enzyme, and serum calcium levels all became normal.
Comment
In this patient multisystem sarcoidosis developed approximately three months after the start of interferonribavirin and underwent natural remission once the drug was stopped. The occurrence of hypercalciuria in the patients with interferon-induced sarcoidosis has not been reported before.
Case #2
A 53-year-old Caucasian woman was diagnosed with hepatitis C five years prior to this presentation. She was given interferon. Six months after the initiation of therapy, the patient developed moderate dyspnea. A month later she noticed skin nodules on the arms and legs consistent with erythema nodosum. Her old tattoo became hard and tender. A chest x-ray revealed interstitial-nodular infiltrate. The lung function tests, gallium scan, serum angiotensin-converting enzyme and calcium levels were normal. Skin biopsies of the nodules showed noncaseating granulomas.
Comment
In this patient, sarcoidosis ushered in with reactivation of the previous tattoo scar and erythema nodosum.
Case #3
In 1997, at the age of 63 years, this Hispanic man was given interferon-ribavirin for hepatitis C. He continued the treatment for two years. His liver functions became normal and the viral load came down. A few months later he developed hypothyroidism that was thought to be due to interferon treatment. In 2002, the patient started noticing fatigue. Later when he complained of dyspnea a chest x-ray showed interstitial infiltrate. A transbronchial lung biopsy was performed that showed noncaseating granulomas. The lung function study showed a vital capacity of 75% and diffusing capacity of 65% of predicted normal. He was treated with prednisone 20 mg day. 
Figure 2. Gallium study
Right half of the picture shows an intense Gallium uptake signifying active granulomatous inflammation. The left half shows almost a normal Gallium uptake representing the disease remission.
Comment
In this patient sarcoidosis developed after the two-year course of interferon was completed. First the patient developed two clinical syndromes related to interferon; first hypothyroidism and then sarcoidosis. His sarcoidosis was mild; it responded to treatment.
Discussion
Sarcoidosis is a multisystem granulomatous disorder of unknown etiology, most commonly affecting adults between 20 to 50 years in age and presenting most frequently with bilateral hilar adenopathy with or without pulmonary infiltration, and with skin, eye, peripheral lymph nodes, liver, spleen, and joint involvement [6]. In fact, no organ is left untouched by the disease process. The diagnosis is established most securely when clinicoradiologic findings are supported by histologic evidence of widespread noncaseating-epithelioid granulomas in the involved tissue. The granuloma formation is antigen driven and reflects hyperactivity of the immune system. The first sign of granuloma is an accumulation of T lymphocytes and mononuclear-macrophages. The next step is the organization of granuloma, a cluster of highly dynamic epithelioid and multinucleated, Th1 and Th2, and B-cells that spontaneously produce a variety of cytokines. Th1 cells produce interferon-␥ and Interleukin-2 (IL-2). Interferon-␥, also produced by activated macrophages, plays a major role in activation of macrophages and differentiation of mononuclear cells into epithelioid cells.
How does exogenously given interferon-␣ cause the granulomatous syndrome?
Interferon-␣ and -␤ are in the class I interferon family, whereas interferon-␥ belongs to class II. It has been suggested that class I and II interferons share signal transduction pathways [5]. Exogenously administered interferon-␣ and interferon-␤ can activate macrophages in vitro [7] . Interferon-␣ influences the production of interferon-␥, reduces the activation of Th2 lymphocytes, increases the expression of mRNA coding for IL-12, and together with IL2 leads to Th1 differentiation and increased production of the corresponding cytokines.
Ribavirin, a nucleoside analogue of guanosine is an active medication, in vivo and in vitro, against RNA and DNA viruses. Because of its virostatic activity it is used in treating many viral infections. Ribavirin enhances the Th-1 response by increasing the production and expression of IL-12 mRNA, by increasing production of interferon-␥ and tumor necrosis factor, and decreasing the Th-2 response [8, 9] . The superiority of the interferon ␣-Ribavirin combination in enhancing the Th1-type immune response may be responsible for an exaggerated granulomatous response [10] . Mice immunized with HCV core protein in the presence of ribavirin showed increased production of IL-12 that promotes the differentiation of CD4 cells to Th1 cells [11] .
Does systemic sarcoidosis differ from the type of sarcoidosis induced by interferon-␣ or the combination of interferon-␣ and ribavirin?
To our knowledge there are only 30 cases of interferoninduced sarcoidosis in the English literature (Tables 1  and 2) . Studies [12, 16, 17, 18] were reported by Nawras et al. [13•] . The total number now is 33.
Only 2 of 30 (6.7%) had a previous history of sarcoidosis [16, 22] . Thus in 31 patients sarcoidosis appeared after interferon therapy. Twenty-five of thirty-three (75.8%) had evidence of multisystem sarcoidosis [10,11,13•, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] 32] , whereas seven patients had only cutaneous sarcoidosis [10, 12, 15, 21, 24, 28, 31] , and one had only neurosarcoidosis [14] . In 25 of 33 cases (75.8%), interferon-␣ was used to treat hepatitis C (Table 1) ; four cases received the drug for myelogenous leukemia (CML) [25] [26] [27] [28] , and the remaining four had multiple myeloma [29] , multiple sclerosis [31] , and thrombocythemia [32] .
This group of 33 patients included 19 women and 14 men, ranging from 26 to 67 years in age with a mean of (48.61 ± 9.45 years). Fourteen patients received interferon-␣ alone [12,13•,15-19,22,23] ; 12 patients received interferon-␣ and ribavirin [10, 18, 19, 20, 21, 24] ; two patients received interferon-␣, ribavirin, and amantadine [11] ; and three patients were given interferon-␤ [14, 29, 30] . termination of treatment in six [17, 18, 21, 23, 28] . In one of our patients, sarcoidosis appeared approximately 12 to 14 months after the discontinuation of treatment.
In the patients receiving interferon therapy, the appearance of symptoms suggesting a new multisystem disease should lead a physician to think of sarcoidosis as one of the diagnoses. Chest x-ray must be done and serum ACE levels must be measured. We suggest an algorithm to evaluate such a patient (Fig. 4) . Once the diagnosis is established the management is usually easy. In most of the patients sarcoidosis disappears when interferon is discontinued. We have followed one such patient; her sarcoidosis has not recurred during the six-year followup. Furthermore, these patients respond favorably to corticosteroids treatment with or without stopping interferon [25] .
Conclusion
After careful consideration of the findings in all of the above cases surveyed in the English literature, we conclude that interferon therapy can indeed induce or exacerbate sarcoidosis. Interferons lead to a stimulation of the Th-1 response, which plays a major role in the formation of sarcoid granulomas. The superiority of the in-terferon-␣ and ribavirin combination in terms of antiviral action may be corroborated by the enhancing Th1-type immune reaction. It may be that this enhanced immune cell reaction produced a greater granulomatous reaction. Sarcoidosis during interferon therapy can present as systemic, cutaneous, or combined disease. With the increasing use of interferons in various therapeutic applications it is highly likely that more cases of sarcoidosis will be encountered by clinicians. In patients receiving interferons the possibility of sarcoidosis should be highly entertained if there is appearance of symptoms suggesting a new multisystem disease. In most of the patients sarcoidosis disappears when interferon is discontinued; sometimes treatment with corticosteroids is necessary. Based upon our careful review of the cases mentioned above, we propose an algorithm for the management of interferon-induced sarcoidosis.
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